Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia

Table 1

Baseline clinical characteristics of the study patients .

Demographic details	Group TCH	Group TCHP	value
Age (yr)	68.3 ± 6.1	65.7 ± 7.1	0.69
Gender
Females	22 (100%)	23 (100%)	0.95
Menopausal status at diagnosis	23 (100%)	22 (100%)	1.00
Clinical stage at diagnosis
Stage I	1 (2.6)	2 (5.2)	0.99
Stage II	3 (7.8)	1 (2.6)	0.19
Stage III	01 (2.6)	02 (5.2)	0.55
Clinical nodal status
Node positive	115 ± 21.9	122 ± 21.1	0.39
Node negative	80 ± 18.1	78 ± 19.8	0.91
Clinical T stage
T1	3 ± 0.1	3 ± 0.1	1.00
T2	12 ± 0.3	12 ± 0.3	0.83
T3	6 ± 0.2	4 ± 0.2	0.88
T4	2 ± 0.1	1 ± 0.1	0.56
T4d	1 ± 0.1	1 ± 0.1	0.20
Pretreatment LEVF
<55%	03 ± 2.1	05 ± 2.3	0.65
>55%	20 ± 5.3	17 ± 2.7	0.76
ECOG status
0	9/23 (38%)	8/22 (34%)	1.00
1	9/23 (36%)	8/22 (33%)	1.00